Jubilant Radiopharma, a US-based business segment of India-based Jubilant Pharmova Limited, with a network of Radiopharmacies in the United States, announced on Tuesday that it has entered into a strategic partnership with Simplified Imaging Solutions (SIS), a Diagnostic Services Organisation (DSO).
The partnership is aimed at improving the operational efficiencies of nuclear medicine services to healthcare facilities and physician offices nationwide. This is a comprehensive full-service nuclear medicine solution that combines a national network of radiopharmacies with a Diagnostic Services Organisation in the United States.
This partnership integrates the national network of 43 SPECT radiopharmacies and three PET manufacturing facilities of Jubilant Radiopharma with the fixed and mobile diagnostic solutions of Simplified Imaging Solutions. It is intended to provide all products and services ranging from equipment, technicians, management services, FDA approved radiopharmaceuticals, licensing, accreditation, physicists, camera service or any other additional support needed for efficient and affordable testing experience. The aim of the collaboration will be to provide clients with a turnkey, consolidated, lower cost option of offering in-house diagnostics in both existing and new labs.
Harsher Singh, Jubilant Radiopharma CEO, said: "By partnering with Simplified Imaging Solutions, Jubilant Radiopharma is delivering a holistic solution that addresses the operational challenges that our customers face daily. This collaboration will help empower practices to operate more efficiently and profitably, allowing them to focus on patient care."
Endo signs definitive agreement for Paladin Pharma to commercialise Wynzora Cream in Canada
Merck's KEYTRUDA plus chemotherapy receives positive EU opinion for first-line MPM treatment
Sanofi seeks FDA approval for Dupixent in chronic spontaneous urticaria
Azurity Pharmaceuticals' Danziten granted US FDA approval
PTC Therapeutics' gene therapy to treat AADC deficiency receives US FDA accelerated approval
Caliway Biopharmaceuticals' CBL-514 receives EMA Orphan Drug Designation
Jubilant Radiopharma forms collaboration with Simplified Imaging Solutions
Eupraxia Pharmaceuticals reveals additional data from RESOLVE Phase 1b/2a trial of EP-104GI